Multicenter optimization and validation of a 2-gene mRNA urine test for detection of clinically significant prostate cancer prior to initial prostate biopsy

Further Publications Urology

Initial Prostate Health Index (phi) and phi density predicts future risk of clinically significant prostate cancer in men with initial negative prostate biopsy: a 6-year follow-up study

Prostate Cancer Prostatic Dis

Liu AQ, Remmers S, Lau SY, Yip SY, Leung CH, Mak CW, Yee CH, Teoh JY, Hou SM, Roobol M, Ng CF, Chiu PK

doi: 10.1038/s41391-021-00444-y

Uro-Oncology

Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10 ng/mL

Prostate Cancer Prostatic Dis.

Tutrone R, Donovan MJ, Torkler P, Tadigotla V, McLain T, Noerholm M, Skog J, McKiernan J

doi: 10.1038/s41391-020-0237-z.

Uro-Oncology

Detection of clinically significant prostate cancer in biopsy-naïve men: Head-to-head comparison of systematic biopsy, multiparametric MRI- and contrast ultrasound dispersion imaging-targeted biopsy

BJU Int.

Mannaerts CK, Engelbrecht MRW, Postema AW, van Kollenburg RAA, Hoeks CMA, Savci-Heijink CD, Van Sloun RJG, Wildeboer RR, De Reijke TM, Mischi M, Wijkstra H

doi: 10.1111/bju.15093.

Uro-Oncology

Multiparametric MRI-Ultrasound Software Fusion Prostate Biopsy - Initial Results Using A Stereotactic Robotic Assisted Transperineal Prostate Biopsy Platform Comparing Systematic Versus Targeted Biopsy

BJU Int.

Lee AY, Yang XY, Lee HJ, Law YM, Hong HH, Lau WK, Lee LS, Ho HS, Tay KJ, Cheng CW, Yuen JS, Chen K

doi: 10.1111/bju.15118.

Uro-Oncology

External Validation and Comparison of Prostate Cancer Risk Calculators Incorporating Multiparametric Magnetic Resonance Imaging for Prediction of Clinically Significant Prostate Cancer

J Urol.

Saba K, Wettstein MS, Lieger L, Hötker AM, Donati OF, Moch H, Ankerst DP, Poyet C, Sulser T, Eberli D, Mortezavi A

doi: 10.1097/JU.0000000000000622.

Uro-Oncology

Development of a multivariable risk model integrating urinary cell DNA methylation and cell-free RNA data for the detection of significant prostate cancer

Prostate.

Connell SP, O'Reilly E, Tuzova A, Webb M, Hurst R, Mills R, Zhao F, Bapat B, Cooper CS, Perry AS, Clark J, Brewer DS

doi: 10.1002/pros.23968.

Uro-Oncology

Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis

Eur Urol.

Sathianathen NJ, Omer A, Harriss E, Davies L, Kasivisvanathan V, Punwani S, Moore CM, Kastner C, Barrett T, Den Bergh RV, Eddy BA, Gleeson F, Macpherson R, Bryant RJ, Catto JWF, Murphy DG, Hamdy FC, Ahmed HU, Lamb AD

doi: 10.1016/j.eururo.2020.03.048.

Uro-Oncology

Development and initial clinical correlation of a DNA methylation-based blood test for prostate cancer

Prostate.

Carson JJK, Di Lena MA, Berman DM, Siemens DR, Mueller CR

doi: 10.1002/pros.24025.

Uro-Oncology

Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 3: Targeted Biopsy

Eur Urol.

Venderink W, Bomers JG, Overduin CG, Padhani AR, de Lauw GR, Sedelaar MJ, Barentsz JO

doi: 10.1016/j.eururo.2019.10.009.

Related content

Initial Prostate Health Index (phi) and phi density predicts future risk of clinically significant prostate cancer in men with initial negative prostate biopsy: a 6-year follow-up study

Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10 ng/mL

Detection of clinically significant prostate cancer in biopsy-naïve men: Head-to-head comparison of systematic biopsy, multiparametric MRI- and contrast ultrasound dispersion imaging-targeted biopsy

Multiparametric MRI-Ultrasound Software Fusion Prostate Biopsy - Initial Results Using A Stereotactic Robotic Assisted Transperineal Prostate Biopsy Platform Comparing Systematic Versus Targeted Biopsy

External Validation and Comparison of Prostate Cancer Risk Calculators Incorporating Multiparametric Magnetic Resonance Imaging for Prediction of Clinically Significant Prostate Cancer

Development of a multivariable risk model integrating urinary cell DNA methylation and cell-free RNA data for the detection of significant prostate cancer

Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis

Development and initial clinical correlation of a DNA methylation-based blood test for prostate cancer

Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 3: Targeted Biopsy